News & Insights
Key Takeaways
- Allogeneic cell therapies reduce costs and simplify logistics by separating manufacturing from individual patients—enabling faster access to treatment.
- Automation improves manufacturing consistency, minimizes human error, and lowers training requirements, supporting reliable scale-up.
- Flexible manufacturing designs allow therapies to evolve through clinical development while maintaining regulatory compliance.
- Experienced CDMOs play a critical role by providing adaptable platforms and deep expertise across both autologous and allogeneic manufacturing.
Check out the full article at BioPharm International.
